Saturday , July 31 2021

Chile will deliver tablets to prevent the spread of HIV NEWS | Industry

The Chilean government announced it last Friday free delivery on pre-exposure prophylaxis (PREP), a drug that prevents the transmission of HIV; during first quarter of 2019.

For this, authorities in Chile, a country that over the last seven years saw the duplicate of the number of people infected with the virus, met with members of the Movement of homosexual integration and liberation (Movil), in order to define the protocols that govern its use next year.

"Finger pills can reduce the possibility of acquiring the virus by more than 90% during sexual practices if taken daily. Therefore, there must be a protocol that guides people on its real effects and encourages them to support safe sexual practices, because it's not the idea that the pill causes relaxation, "said Movilh Health Area manager Diego Rios.

According to the Minister of Health, Emilio Santelles, the PREP pill is part of a new AIDS and HIV plan, and will be used as a preventive treatment in high-risk populations.

How does it function?

According to the US Centers for Disease Control and Prevention (CDC), if PrEP is taken daily, you receive decreased by more than 90% the chances of engaging the virus that causes AIDS through sex or 70% using needles that are not sterilized or used by more people.

PrEP contains emtricitabine and tenofovir, two drugs that are also used in antiretroviruses, because they reduce the amount of blood in the blood and prevent it from multiplying.

Pills do not function as a vaccine because they do not generate antibodies, but that their daily intake is necessary, so that emcicytabine and tenofovir are present in the blood at the moment of infection and prevent HIV from being found in the body.

Before you enter it, it is necessary to confirm the good state of the kidneys and liver, because the pill may cause disorders in these organs.

More information

It was the American pharmaceutical company Gilead Sciences that began marketing this drug in 2012, under the brand name Truvada. It is estimated that the commercial value of the monthly treatment reaches $ 600.

Years later, the World Health Organization (WHO) began recommending its use to prevent HIV among high-risk groups, such as sex workers or couples of infected patients.


According to data from Onusida, referring to 2017, there are 67,000 people infected with HIV in Chile, of which 39,001 are in treatment, while projections indicate an increase of those affected to 100,000 by the end of this year.

Source link